Docking and in silico ADMET studies of noraristeromycin, curcumin and its derivatives with Plasmodium falciparum SAH hydrolase: A molecular drug target against malaria

Interdisciplinary Sciences – Computational Life Sciences

Volumn 5, Issue 1, 2013, Pages 1-12

  Singh, Dev Bukhsh ^a   Gupta, Manish Kumar ^a   Singh, Durg Vijay ^a   Singh, Sushil Kumar ^b   Misra, Krishna ^c  

^a CSJM UNIVERSITY   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^c INDIAN INSTITUTE OF INFORMATION TECHNOLOGY   (India)

Author keywords

ADMET; anti malarial; curcumin; docking; malaria; noraristeromycin; pfSAHH

Indexed keywords

PLASMODIUM FALCIPARUM;

EID: 84883287025     PISSN: 19132751     EISSN: 18671462     Source Type: Journal    
DOI: 10.1007/s12539-013-0147-z     Document Type: Article

References (42)

1. Ando, T., Kojima, K., Chahota, P., Kozaki, A., Milind, N. D., Kitade, Y. 2008. Synthesis of 4′-modified noraristeromycins to clarify the effect of the 4′-hydroxyl groups for inhibitory activity against Sadenosyl-l-homocysteine hydrolase. Bioorg Med Chem Lett 18, 2615-2618.
2. Brady, R. L., Cameron, A. 2004. Structure-based approaches to the development of novel anti-malarials. Curr Drug Targets, 137-149.
3. Efferth, T., Herrmann, F., Tahrani, A., Wink, M. 2011. Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine 18, 959-969.
4. Ertl, P., Rohde, B., Selzer, P. 2000. Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties. J Med Chem 43, 3714-3417.
5. Garah, F. B., Stigliani, J. L., Cosldan, F., Meunier, B., Robert, A. 2009. Docking studies of structurally diverse antimalarial drugs targeting PfATP6: No correlation between in silico binding affinity and in vitro antimalarial activity. ChemMedChem 4, 1469-1479.
6. Ji, H. F., Shen, L. 2009. Interactions of curcumin with the PfATP6 model and the implications for its antimalarial mechanism. Bioorg Med Chem Lett 19, 2453-2455.
7. Jorgensen, W. L. 1998. BOSS - Biochemical and organic simulation system. In: Schleyer, P. V. R. (Ed.) The Encyclopedia of Computational Chemistry, John Wiley & Sons Ltd., Athens, USA, 3281-3285.
8. 2+-ATPase (PfATP6) and docking of artemisinin derivatives to PfATP6. Bioorg Med Chem Lett 15, 2994-2997.
9. Kalani, K., Yadav, D. K., Khan, F., Srivastava, S. K., Suri, N. 2011. Pharmacophore, QSAR and ADME based semi-synthesis and in-vitro evaluation of ursolic acid analogs for anti-cancer activity. J Mol Model 8, 3389-3413.
10. Kitade, Y., Kozaki, A., Miwa, T., Nakanishi, M., Yatome, C. 2000. Synthesis of carbocyclic nucleosides and their SAH hydrolase inhibitory activities. Nucleic Acids Symp Ser 44, 111-112.
11. Kitade, Y., Kojima, H., Zulfiqur, F., Kim, H. S., Wataya, Y. 2003a. Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. Bioorg Med Chem Lett 13, 3963-3965.
12. Kitade, Y., Kojima, H., Zulfiqur, F., Yabe, S., Yamagiwa, D., Ito, Y., Nakanishi, M., Ueno, Y., Kim, H. S., Wataya, Y. 2003b. Synthesis of carbocyclic and acyclic nucleosides possessing 2-fluoroadenine derivatives and their inhibitory activities against Plasmodium falciparum SAH hydrolase. Nucl Acid Res (Suppl. 3), 5-6.
13. Kojima, H., Yamaguchi, T., Kozaki, A., Nakanishi, M., Ueno, Y., Kitade, Y. 2002. Synthesis of noraristeromycin analogues possessing SAH hydrolase inhibitory activity for the development of antimalaria agents. Nucl Acid Res (Suppl. 2), 141-142.
14. Lipinski, C. A., Lombardo, F., Dominy, B. W., Fenney, P. J. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3-26.
15. Lowe, R., Glen, R., Mitchell, J. B. O. 2010. Predicting phospholipidosis using machine learning. Mol Pharm 7, 1708-1714.
16. Matthews, E. J., Kruhlak, N. L., Benz, R. D., Contrera, J. F. 2004a. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Curr Drug Disc Tech 1, 61-76.
17. Matthews, E. J., Kruhlak, N. L., Weaver, J. L., Benz, R. D., Contrera, J. F. 2004b. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Curr Drug Disc Tech 1, 243-254.
18. Meena, A., Yadav, D. K., Srivastava, A., Khan, F., Chanda, D, Chattopadhyay, S. K. 2011. In silico exploration of anti-inflammatory activity of natural Coumarinolignoids. Chem Biol Drug Des 78, 567-579.
19. Mimche, P. N., Taramelli, D., Vivas, L. 2011. The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malar J 15, 10Suppl 1, S10.
20. Mithani, S. D., Bakatselou, V., TenHoor, C. N., Dressman, J. B. 1996. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 13, 163-167.
21. 2+-ATPase (PfATP6). J Mol Model 17, 333-357.
22. Nakanishi, M., Yabe, S., Tanaka, N., Ito, Y., Nakamura, K. T., Kitade, Y. 2005. Mutational analyses of Plasmodium falciparum and human Sadenosylhomocysteine hydrolases. Mol Biochem Parasitol 143, 146-151.
23. Padmanaban, G., Nagaraj, V. A., Rangarajan, P. N. 2007. Drugs and drug targets against malaria. Curr Sci 92, 1545-1555.
24. Pajeva, I. K., Globisch, C., Wiese, M. 2009. Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. Chem Med Chem 4, 1883-1896.
25. Rasoanaivo, P., Wright, C. W., Willcox, M. L., Gilbert, B. 2011. Whole plant extracts versus single compounds for the treatment of malaria: Synergy and positive interactions. Malar J 15, 10 Suppl 1, S4.
26. Reddy, R. C., Vatsala, P. G., Keshamouni, V. G., Padmanaban, G., Rangarajan, P. N. 2005. Curcumin for malaria therapy. Biochem Biophys Res Commun 326, 472-474.
27. Sadowski, J., Gasteiger, J., Klebe, G. 1994. Comparison of automatic three-dimensional model builders using 639 X-ray structures. J Chem Inf Comput Sci 34, 1000-1008.
28. Sanguinetti, M. C., Tristani-Firouzi, M. 2006. hERG potassium channels and cardiac arrhythmia. Nature 440, 463-469.
29. Sharma, S. K., Kapoor, M., Ramya, T. N., Kumar, S., Kumar, G., Modak, R., Sharma, S., Surolia, N., Surolia, A. 2003. Identification, characterization, and inhibition of Plasmodium falciparum beta-hydroxyacylacyl carrier protein dehydratase (FabZ). J Biol Chem 278, 45661-45671.
30. Shi, W., Ting, L. M., Kicska, G. A., Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., Kim, K., Almo, S. C., Schramm, V. L. 2004. Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function. J Biol Chem 279, 18103-18106.
31. Singh, D. V., Agarwal, S., Kesharwani, R. K., Misra, K. 2012. Molecular modeling and computational simulation of the photosystem-II reaction center to address isoproturon resistance in Phalaris minor. J Mol Model 18, 3903-3913.
32. Singh, D. B., Gupta, M. K., Kesharwani, R. K., Misra, K. 2013. Comparative docking and ADMET study of some curcumin derivatives and herbal congeners targeting β-amyloid. Netw Model Anal Health Inform Bioinforma 2, 13-27.
33. Tagboto, S., Townson, S. 2001. Antiparasitic properties of medicinal plants and other naturally occurring products. Adv Parasitol 50, 199-295.
34. Tanaka, N., Nakanishi, M., Kusakabe, Y., Shiraiwa, K., Yabe, S., Ito, Y., Kitade, Y., Nakamura, K. T. 2004. Crystal structure of S-adenosyl-L-homocysteine hydrolase from the human malaria parasite Plasmodium falciparum. J Mol Biol 343, 1007-1017.
35. Thomsen, R., Christensen, M. H. 2006. MolDock: A new technique for high-accuracy molecular docking. J Med Chem 49, 3315-3321.
36. Tschan, S., Mordmller, B., Kun, J. F. 2011. Threonine peptidases as drug targets against malaria. Expert Opin Ther Targets, 365-378.
37. Wang, J. 2009. Comprehensive assessment of ADME risks in drug discovery. Curr Pharm 15, 2195-2219.
38. Yadav, D. K., Khan, F., Negi, A. S. 2011. Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity. J Mol Model 18, 2513-2525.
39. Yadav, D. K., Meena, A., Srivastava, A., Chanda, D., Khan, F., Chattopadhyay, S. K. 2010. Development of QSAR model for immunomodulatory activity of natural Coumarinolignoids. Drug Design, Development & Therapy 4, 173-186.
40. Yang, J., Chen, C. 2004. GEMDOCK: A generic evolutionary method for molecular docking. Proteins 55, 288-304.
41. Yang, X., Hu, Y., Yin, D. H., Turner, M. A., Wang, M., Borchardt, R. T., Howell, P. L., Kuczera, K., Schowen, R. L. 2003. Catalytic strategy of S-adenosyl-L-homocysteine hydrolase: Transition-state stabilization and the avoidance of abortive reactions. Biochemistry 42, 1900-1909.
42. Yuan, C. S., Saso, Y., Lazarides, E., Borchardt, R. T., Robins, M. J. 1999. Recent advances in S-adenosyl-L-homocysteine hydrolase inhibitors and their potential clinical applications. Expert Opin Ther Patents 9, 1197-1206.